Somatostatin is a cyclic 14-amino acid peptide first isolated from the hypothalamus as a physiological inhibitor of growth hormone secretion (1, 2) . Subsequently, somatostatin has been shown to have a widespread distribution and to participate in a variety of biological processes including inflammatory reaction. Immunoreactive somatostatin has been detected in the cytoplasm of macrophages, fibroblasts, and endothelial cells at the site of carrageenin-induced aseptic inflammation in rat (3) . Likewise, somatostatin and preprosomatostatin mRNA have been demonstrated in granuloma cells, mainly macrophages, surrounding parasites in mice infected with Schistosoma mansoni (4) . Such an expression of somatostatin is thought to limit inflammatory processes. Indeed, in vivo administration of octreotide, a stable somatostatin analogue, decreases the volume and the leukocyte concentration of the exudate in carrageenininduced inflammation (5) and reduces granuloma size in Schistosomiasis mansoni (6) . A number of signaling events are potentially important in this anti-inflammatory response. Among them is the ability of somatostatin to interact with T cells (7), neutrophils, and macrophages to inhibit interferon-␥ release (4), elastase release (8) , and tumor necrosis factor-␣ (TNF-␣) 1 binding (9), respectively. In addition, somatostatin participates in the anti-inflammatory actions of glucocorticoids. For instance, in the model of carrageenin-induced acute inflammation, administration of dexamethasone increases the expression of immunoreactive somatostatin in inflammatory cells, whereas administration of anti-somatostatin antiserum prevents the dexamethasone-mediated blockade of leukocyte accumulation (3) . The molecular mechanisms whereby somatostatin would induce glucocorticoid responsiveness in target cells remain unknown.
In the present study, we tested the hypothesis that somatostatin increases glucocorticoid responsiveness by up-regulating GR expression. This concept is supported by findings of a direct correlation between the concentration of GR in a target cell and the sensitivity of this cell to glucocorticoids (10) . In addition, the cell concentration of GR has been already shown to be modulated by a number of mediators including glucocorticoids, cAMP-inducing agonists, and cytokines such as TNF-␣ and interleukin-2, -4, and -13 (11) (12) (13) (14) (15) . We found that somatostatin increases glucocorticoid binding and signaling in RAW 264.7 macrophages. This increase is not related to an increased expression of GR but represents a stabilization of GR-associated Hsp 90 due to calpain inhibition.
EXPERIMENTAL PROCEDURES
Cell Culture-The mouse cell line RAW 264.7 was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Cells were grown to confluence in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in a 5% CO 2 , 95% air atmosphere. They were exposed to somatostatin (Sigma) and/or * This work was supported in part by INSERM and by the Faculté de Médecine Saint-Antoine. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 
Thioglycollate-elicited macrophages were harvested from the peritoneal cavity of 12-week-old BALB/c mice, as described previously (16) .
Glucocorticoid Receptor Assay-A whole cell binding assay was used to determine GR number and affinity in untreated and somatostatintreated cells (16) (32 nM) . Unlabeled dexamethasone was used at a concentration of 10 M. After incubation for 2 h at 37°C, monolayers were washed 6 times with cold phosphatebuffered saline, and cells were lysed in 1 N NaOH. Lysates were harvested and counted in a beta spectrometer.
RNase Protection Assay (RPA)-To quantitate GR mRNA levels, RPA was performed as described previously (17) . RNA was co-hybridized with radiolabeled probes for mouse GR, ␤-actin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Mouse GR probe was synthesized by using a cDNA insert in Bluescript plasmid (generous gift from G. Schuetz, Heidelberg, Germany). This probe contains 307 nucleotides, of which 234 are protected by hybridization to the mGR mRNA (residues 2113-2347). Mouse ␤-actin probe was synthesized using a cDNA insert in PGEM-3 plasmid (generous gift from D. Alvarado, Paris, France). This probe contains 190 nucleotides, of which 135 are protected by hybridization to the ␤-actin mRNA (residues 696 -833). Rat GAPDH probe was synthesized using a cDNA insert in a pBluescript plasmid (generous gift from C. Dani, Nice, France). This probe contains 183 nucleotides, of which 164 are protected by hybridization to the GAPDH mRNA (residues 707-871). The results were normalized and expressed as the GR mRNA/␤-actin mRNA ratio or the GR mRNA/GAPDH mRNA ratio (arbitrary units).
Semi-quantitative Reverse Transcriptase-PCR and Analysis of PCR Products-Total RNA was isolated using a commercially available kit (RNABle, Eurobio, Les Ulis, France) according to the manufacturer's instructions. One g of total RNA was reverse-transcribed to cDNA by using avian myeloblastosis virus-reverse transcriptase (10 units/l; Promega, Charbonnieres, France). Reverse-transcribed samples were analyzed for Hsp 84-and ␤-actin-specific cDNA by PCR amplification. Specific primers for Hsp 84 and ␤-actin were as follows: GAAGATTC-CACTAACCGCCG (sense) and CCATTGTAGAGT-TGTCTCGC (antisense); CAAGGTGTGATGGTGGGAAT (sense) and GTCATCT-TT-TCACGGTTGGC (antisense), respectively (18) . PCR was performed in a 20-l reaction volume containing Taq polymerase buffer, deoxynucleotide mixture (0.2 mM each), MgCl 2 (2.5 mM), Taq DNA polymerase (0.5 units) (Promega), oligonucleotide primers (0.5 M each), and reversetranscribed RNA. Complementary DNA was amplified in a temperature cycler as follows: 5 min at 94°C, and 26 cycles of 45 s at 94°C, 1 min at 60°C, and 1 min at 72°C, with a final extension step of 10 min at 72°C. Twenty six PCR cycles were found in the exponential phases of PCR amplification of both Hsp 84 and ␤-actin cDNA. Fifteen-l samples of PCR products were analyzed on 2% agarose gels containing 0.2 g/ml ethidium bromide. Densitometry of the bands was performed on the gels using an Imager scanner (Appligene, Illkirch, France) and NIH image densitometry software (version 1.44). The results were expressed as the ratio of the optical density of Hsp 84 band/␤-actin band.
Western Blotting-Medium was removed from culture dishes, and RAW 264.7 cells were resuspended using a cell scraper in 1.5 ml of phosphate-buffered saline. The cells were then pelleted by centrifugation (600 ϫ g, 4°C for 10 min), frozen at Ϫ70°C for 4 h, thawed, and resuspended in 100 l of ice-cold protease inhibitory buffer (1 mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, 20 g/ml aprotinin in 50 mM Tris (pH 7.4), 100 mM NaCl, 2 mM EDTA, and 1% Nonidet P-40). The lysate was centrifuged (4 000 ϫ g, 4°C for 30 min). A 10-l portion of the supernatants was reserved for protein determination, and protein concentration in supernatant samples was adjusted with the protease inhibitory buffer. These samples were boiled for 3 min in Laemmli loading buffer and subjected to electrophoresis on a 7.5% polyacrylamide-SDS gel. Proteins were electroeluted onto a nitrocellulose membrane (Immobilon-P, Millipore, Bedford, MA) that was stained with Ponceau S (0.5% in 1% acetic acid) to ensure uniformity of loading and transfer. After destaining with water, the membrane was blocked for 18 h at 4°C in 10% nonfat dry milk solution in phosphate-buffered saline ϩ 0.1% Tween. GR was detected using a polyclonal antibody (1:100 dilution; Affinity Bioreagents, Golden, CO); Hsp 84 was detected using either a polyclonal antibody raised against the amino-terminal domain of the molecule (1:200 dilution; Affinity Bioreagents) or a polyclonal antibody raised against the carboxyl-terminal domain of the molecule (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), and Hsp 86 was detected using a polyclonal antibody (1:2 000 dilution; Affinity Bioreagents). Primary antibody incubations were followed by incubations with peroxidase-labeled anti-IgG secondary antibody (1: 20,000 dilution). Then the membrane was developed with the ECL detection reagent (Amersham Pharmacia Biotech).
Calpain Assay-The calpain-like activity was determined in intact cells, as described (19) . RAW 264.7 cells were plated in Dulbecco's modified Eagle's medium supplemented with 2.5% FBS in 6-well tissue culture dishes, at 5 ϫ 10 6 cells per well. After the indicated culture period, the medium was replaced with Krebs-Ringer buffer solution (pH 7.4) containing 1.8 mM CaCl 2 0.2% bovine serum albumin, and 20 M Suc-Leu-Leu-Val-Tyr-AMC (Calbiochem), a membrane-permeant calpain protease substrate. The incubation was continued for 10 min at 37°C. AMC fluorescence was then determined in the supernatant at 360 nm excitation and 430 nm emission. An AMC (Sigma) standard curve was generated for each experiment. Calpain activity was expressed in picomoles of AMC released per min of incubation time per well. The measurement of AMC fluorescence in the supernatant was previously validated by demonstrating that AMC did not accumulate in cultured cells (19) .
Electrophoretic Mobility Shift Assay (EMSA)-RAW 264.7 cells were incubated with or without 250 nM dexamethasone for 3 h and then stimulated with or without 1 g/ml LPS for 1 h. Nuclear extracts were prepared by the method described previously (20) and were stored at Ϫ80°C until analysis. Protein was determined by using the Bio-Rad reagent (Bio-Rad) according to the manufacturer's instructions. EMSA was as described (20) using the double-stranded NF-B site probe 5Ј-AGCTTCAGAGGGGACTTTCCGAGAGG-3Ј and 3Ј-AGTCTCCCCT-GAAAGGCTCTCCA-GCT-5Ј (21) .
Transient Transfection of RAW 264.7 Cells and Luciferase Assay-RAW 264.7 cells were transfected with (GRE) 2 TK luciferase, a glucocorticoid-inducible reporter plasmid containing a minimal promoter with two consensus GRE upstream of the gene for luciferase (generous gift from Dr. M.-G. Catelli, CNRS UPR 1524, Paris, France), using the DEAE-dextran procedure (22) . Luciferase activity was assayed as described (23) .
Statistics-Results are presented as the mean Ϯ S.E. Statistical analysis was performed using the Mann Whitney U test. Statistical significance was defined as p Ͻ 0.05. (Fig. 1A) . Maximal effect was seen at a somatostatin concentration of 10 nM. For this concentration, increase in [ 3 H]dexamethasone-specific binding appeared after 2 h of exposure and peaked at 8 -24 h. In contrast, CTAP, a somatostatin analogue with low affinity for somatostatin receptors (24) was inactive at concentrations Յ100 nM.
RESULTS

Somatostatin Increases Glucocorticoid Binding in the Macro
To determine whether somatostatin treatment led to an increase in GR number or affinity, saturation binding and Scatchard analysis were performed (Fig. 1B) ]dexamethasone-binding sites, further analysis evaluated the effect of somatostatin on GR expression at both the mRNA and protein levels. Time course of the effect of 10 nM somatostatin on GR mRNA levels in RAW 264.7 cells was analyzed using a specific RPA. There were no significant changes in the GR mRNA/␤-actin mRNA ratio or the GR mRNA/GAPDH mRNA ratio with somatostatin incubation up to 48 h ( Fig. 2A) . Then, the dose-dependent effect of somatostatin on GR expression in RAW 264.7 cells was assessed using Western blot analysis. Exposure of cells for 18 h to somatostatin doses up to 10 nM did not affect GR protein expression visibly (Fig. 2B) . Above this concentration, GR protein levels fell slightly.
In addition to GR, GR heterocomplex includes heat shock proteins Hsp 56, Hsp 70, and Hsp 90 (25) . The Hsp 90 chaperone, i.e. Hsp 90␣ (Hsp 86) and/or Hsp 90␤ (Hsp 84) (26), must be bound to GR for allowing the hormone binding domain to be in a ligand binding conformation (27) . Thus, to determine whether somatostatin might increase [
3 H]dexamethasone binding indirectly by up-regulating Hsp 90, somatostatin effect on Hsp 90 expression was determined at both the mRNA and protein levels. Time course of the effect of 10 nM somatostatin on Hsp 84 mRNA levels in RAW 264.7 cells was assessed using a semi-quantitative reverse transcriptase-PCR analysis. There was no difference in the Hsp 84/␤-actin ratio between control and somatostatin-treated cells (0.95 Ϯ 0.28 and 0.84 Ϯ 0.09, respectively, at 2 h; 0.93 Ϯ 0.07 and 0.77 Ϯ 0.14, respectively, at 6 h; 1.25 Ϯ 0.22 and 1.12 Ϯ 0.27, respectively, at 24 h). Then, the dose-dependent effect of somatostatin on Hsp 84 expression in RAW 264.7 cells was assessed using Western blot analysis. Hsp 84 was expressed in untreated RAW 264.7 cells as a protein with the expected molecular mass (ϳ84 kDa) and an additional protein with a lower molecular mass (ϳ75 kDa) (Fig. 3A) . Incubation of cells with somatostatin for 18 h resulted in an increase in 84-kDa protein and a dose-dependent disappearance of 75-kDa protein. Western blot analysis of Hsp 86 provided roughly identical results (Fig. 3B) . The results are taken as an indication that 1) the 75-kDa protein is a cleavage product of Hsp 90 and 2) somatostatin prevents this cleavage. Given that the polyclonal anti-Hsp 84 antibody used in Western blot analysis reacts with the amino-terminal domain of the molecule, the detectable cleavage product of Hsp 84 would include that domain. Thus, for comparison, additional Western blot analysis was performed with a polyclonal anti-Hsp 84 antibody directed against the carboxyl-terminal domain of the molecule. As illustrated in Fig. 3C 
FIG. 2. Effect of somatostatin on GR expression.
A, analysis by RPA of the time-dependent expression of mRNA for GR, ␤-actin, and GAPDH. RAW 264.7 cells were incubated with or without 10 nM somatostatin for the indicated periods. One representative experiment out of 3 is shown. B, Western blot analysis of the dose-dependent effect of somatostatin on GR protein level. RAW 264.7 cells were exposed to the indicated concentrations of somatostatin for 18 h. One representative experiment out of 2 is shown.
analysis revealed that the addition of somatostatin (10 nM) resulted in a rapid decrease in calpain activity that peaked at 2 h (data not shown). Fig. 4A depicts the dose response observed at this time point.
Thereafter, the effect of calpain inhibitor 1 on Hsp 90 cleavage was assessed using Western blot analysis. Cell exposure to 10 M calpain inhibitor 1 for 2 h prevented the appearance of the ϳ75-kDa breakdown product (Fig. 4B) . The stabilization of Hsp 90 was associated with a significant increase in [ 3 H]dexamethasone-specific binding (Fig. 5A) . RAW 264.7 cells were also exposed to somatostatin and calpain inhibitor I in combination (Fig. 5B) . The observation that somatostatin increased [ 3 H]dexamethasone-specific binding to the same extent as the combination of somatostatin and calpain inhibitor I at maximally effective doses of each individual molecule supported a role for calpain inhibition in somatostatin response.
Given that calpain inhibitor I might decrease the enzyme activity of the proteasome in addition to that of calpains (29), we compared the response to calpeptin and to Z-IE(O-t-Bu)Aleucinal, two potent and more selective inhibitors of calpain and proteasome pathways, respectively. Calpeptin was more active than Z-IE(O-t-Bu)A-leucinal in increasing [ 3 H]dexamethasone binding (Fig. 5C) , clearly indicating the importance of calpains in this process.
Somatostatin Enhances Glucocorticoid Signaling-We assessed whether the changes in glucocorticoid binding after somatostatin treatment were associated with changes in glucocorticoid signaling. Given that glucocorticoids regulate gene transcription via the binding of GR to GRE or the interaction of GR with different transcription factors (30) , either signaling pathway was studied. First, to analyze the binding of GR to GRE, we used a reporter gene that contains two copies of the GRE. Exposure of RAW 264.7 cells transfected with (GRE) 2 TK luciferase to dexamethasone for 24 h resulted in a dose-dependent increase in luciferase activity (Fig. 6A) . This response was enhanced (ϫ 1.7) by the cell pre-exposure to 10 nM somatostatin.
Second, we determined by EMSA the ability of dexamethasone to suppress the DNA binding activity of NF-B. This regulation has been attributed to both induction of the IB␣ inhibitory protein and direct interaction between the NF-B heterodimer and the GR (31). Exposure of RAW 264.7 cells to LPS for 1 h increased DNA binding activity of NF-B, as evidenced by the increased intensity of the retarded band (Fig.  6B ). Competition assay with the cold NF-B oligonucleotide (Fig. 6B ) and supershifts performed with antisera to p50 and p65 (data not shown) revealed that this band was specific and involved the presence of p50⅐p65 heterodimers, respectively. Exposure of RAW 264.7 cells to dexamethasone led to a dosedependent decrease in LPS-induced NF-B activation. Somatostatin enhanced this response, solely at the lowest dose of dexamethasone tested.
DISCUSSION
The data presented in this study show that somatostatin increases glucocorticoid binding and signaling in macrophages and that this response is associated with the stabilization of Hsp 90, a component of the GR heterocomplex. That somatostatin increases [ 3 H]dexamethasone binding to RAW 264.7 macrophages confirmed that monocytes/macrophages may be a target for somatostatin. Previous studies have shown that exposure of human monocyte-derived macrophages and murine macrophage cell line RAW 264.7 to somatostatin decreases TNF-␣ responsiveness and chemotactic activity, re- spectively (9, 32) . In the current studies, the actions of somatostatin are probably mediated by specific somatostatin receptors as a somatostatin analogue with low affinity for somatostatin receptors was inactive. Five receptor subtypes have been cloned and shown to be coupled to a variety of signal transduction pathways including inhibition of adenylate cyclase, modulation of ionic conductance channels, and protein dephosphorylation (33) . To date, the identity of somatostatin receptors at the surface of monocytes/macrophages has not been reported.
Scatchard analysis of the data indicated that somatostatin increased the number of binding sites for [ 3 H]dexamethasone, whereas the GR binding affinity was not significantly affected. This might be related to a de novo synthesis of GR. Consistent with this hypothesis are the recent findings that somatostatin binds to the 86-kDa subunit of Ku autoantigen (p86-Ku) (34) . The p86-Ku protein, which is localized at the cell surface and within both the cytoplasm and the nucleus, is involved in the positive control of GR gene transcription (35) . Although no direct evidence exists, these findings suggest that somatostatin might promote GR gene transcription through the activation of p86-Ku. However, this mechanism seems unlikely in our model since somatostatin did not increase the steady state levels of GR mRNA and GR. Even GR level was slightly decreased by somatostatin at concentrations above 10 nM (Fig. 2B) .
Several findings of the present study suggest that the effects of somatostatin on glucocorticoid binding are rather indirect effects on Hsp 90. The requirement of Hsp 90 for glucocorticoid binding to GR has been previously demonstrated (reviewed in Ref. 27 ). Assembly of GR-Hsp 90 complexes promotes a folding change of the GR hormone binding domain so that the hydrophobic binding pocket becomes accessible to the ligand (36) . In the mouse, GR binds homodimers of Hsp 86 or Hsp 84 or heterodimers of Hsp 86 and Hsp 84 (27) . In our study, Western blotting analysis using an antibody directed against the carboxyl-terminal domain of Hsp 84 revealed only one molecular form of Hsp 84 with the predicted molecular weight, whereas Western blotting analysis using an antibody directed against the amino-terminal domain of Hsp 84 revealed two distinct molecular forms of Hsp 84 with a molecular mass of ϳ84 and ϳ75 kDa, respectively (Fig. 3) . This indicates that a part of Hsp 84 molecules are truncated leading to the formation of shorter molecules including the amino-terminal domain. Somatostatin diminished the amount of 75-kDa protein in parallel with an increase in the amount of intact 84-kDa protein. This suggests that somatostatin inhibits the cleavage of the Hsp 84 carboxylterminal domain. Since the carboxyl-terminal 10 -15-kDa region of Hsp 84 contains both the dimerization site (28) and the domain that interacts with the hormone binding domain of GR (27) , somatostatin would enhance the assembly of GR⅐Hsp 84 complexes. As a consequence, somatostatin would increase the level of high affinity species of GR through the conversion of nonbinding to binding species.
A second central finding of this study was that the marked stabilization of Hsp 84 induced by somatostatin was associated with a decrease in calpain activity. There are two major isoforms of calpain, and m, which require micro-and millimolar Ca 2ϩ concentrations for activity in vitro, respectively (37). Purified -and m-calpain have been reported previously to cleave the carboxyl-terminal domain of purified Hsp 84 (28) . This probably reflects the ability of Hsp 90 isoforms to bind calmodulin (38) , a characteristic shared by various calpain substrates (39) . Our study adds to these data by demonstrating the importance of endogenous calpains. Calpain inhibitors both prevented Hsp 84 cleavage and increased [ 3 H]dexamethasone binding. In combination, calpain inhibitor I and somatostatin had no additive effects. Therefore, the cause for the observed stabilization of Hsp 84 and increase in [ 3 H]dexamethasone binding relates to activities that are common to both calpain inhibitor I and somatostatin, i.e. calpain inhibition. The finding that somatostatin blunted calpain activity in RAW 264.7 cells provided further evidence for this mechanism.
The complex control of calpain activity affords many potential sites for a regulatory action of somatostatin. First, calpains co-exist in cells with calpastatin that functions as an inhibitor with high affinity and specificity for calpains (37) . The amount of this inhibitor and its relative concentration with respect to calpains modulate the activity of calpains. Thus, somatostatin might affect the abundance of calpains and/or calpastatin by modifying the transcription of either gene. However, modulating enzyme activity through changes in transcription represents a relatively slow regulatory mechanism. The rapid kinetics of calpain inhibition by somatostatin (Ͻ2 h) favor a more direct mechanism such as post-translational modification by specific phosphorylation-dephosphorylation of calpains or calpastatin. In line with this interpretation, observations argue strongly that phosphorylation can alter calpastatin function (40) and possibly calpain function (37) . In addition, somatostatin might modify the phosphorylation status of calpain substrate that affects the sensitivity to calpain cleavage (41) . Finally, the possibility exists that somatostatin binding to RAW 264.7 cells leads to a fall in Ca 2ϩ influx (33) , thereby allowing a decrease in calcium-dependent activity of calpains.
By contrast with somatostatin, glucocorticoids are believed to up-regulate the activity of calpains. Increases in calpain gene transcription and calpain expression contribute to this regulation in a tissue-or a cell-specific manner (42) (43) (44) (45) . Thus, our data imply that glucocorticoids could limit their own binding to GR by up-regulating calpain activity. Somatostatin would prevent such a negative feedback.
GR association with the Hsp 90 complex modifies GR folding and, hence, gives rise to a molecular conformation with a high affinity for the ligand. However the Hsp 90 association also FIG. 6 . Effect of somatostatin on glucocorticoid signaling. A, transactivation of GRE containing promoter. After transfection with the reporter plasmid (GRE) 2 TK luciferase, RAW 264.7 were incubated with (q) or without (E) 10 nM somatostatin for 18 h and with the indicated concentrations of dexamethasone for additional 24 h. Cell extracts were prepared and analyzed for luciferase activity. One representative experiment out of 3 is shown. B, induction of nuclear NF-B activity. RAW 264.7 cells were incubated successively with or without 10 nM somatostatin for 18 h, with or without the indicated concentrations of dexamethasone for 3 h, and with or without 1 g/ml LPS for 1 h. Nuclear extracts from these cells were then analyzed for NF-B DNA binding activity by EMSA. One representative experiment out of 3 is shown.
inactivates GR, either by docking GR heterocomplex in cytoplasmic structures or by inhibiting GR binding to GRE (27, 46) . There is recent evidence that the latter inhibitory function of Hsp 90 prevails when Hsp 90/GR ratio is highly increased, especially in the nucleus (47) . Thus, whether Hsp 90 accumulation following calpain inhibition increases glucocorticoid responsiveness in addition to glucocorticoid binding was questionable. Actually, exposure of RAW 264.7 cells to somatostatin promoted a substantial increase in dexamethasone-mediated transcriptional activation (Fig. 6A) . Furthermore, somatostatin synergistically increased the repressive effects of dexamethasone on DNA binding of NF-B (Fig. 6B ). Together these findings indicate that, upon somatostatin treatment, the rise of Hsp 90/GR ratio is sufficient to increase glucocorticoid binding to GR but not to decrease GR activity.
In conclusion, the data presented demonstrate that somatostatin may participate in the anti-inflammatory actions of glucocorticoids by increasing the binding of glucocorticoids to GR. A mechanism by which somatostatin may mediate these effects is through a decrease in the calpain-specific cleavage of Hsp 90, a component of the GR heterocomplex. Thus, our results also strongly support the concept that calpain inhibition may offer a new and exciting possibility for enhancing glucocorticoid efficiency toward inflammatory reaction.
